Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02947685 · ClinicalTrials.gov registry record · Phase 3

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

A Phase 3 study of Estrogen Receptor-positive Breast Cancer and Her 2 Positive Breast Cancer, sponsored by Alliance Foundation Trials.

Active
Registry status
Phase 3
Development phase
518
Enrollment target
20
Study locations

NCT02947685 is a Phase 3 study of Estrogen Receptor-positive Breast Cancer and Her 2 Positive Breast Cancer that is active but no longer recruiting, run by Alliance Foundation Trials. The registered enrollment target is 518 participants, above the 227-participant average among 16 other Estrogen Receptor-positive Breast Cancer trials with a reported enrollment target (128% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02947685, a Phase 3 study of Estrogen Receptor-positive Breast Cancer and Her 2 Positive Breast Cancer, is active but no longer recruiting, sponsored by Alliance Foundation Trials.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
518 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.

Conditions Studied

Estrogen Receptor-positive Breast Cancer Her 2 Positive Breast Cancer

Interventions

  • DRUG Anastrozole
  • DRUG letrozole
  • DRUG palbociclib
  • DRUG trastuzumab
  • DRUG pertuzumab

Study Locations (20)

Florida

  • Baycare Healthcare (Morton Plant Mease) - Clearwater
  • Memorial Healthcare System - Hollywood
  • University of Miami - Miami
  • Florida Hospital - Orlando

Illinois

  • University of Illinois at Chicago - Chicago
  • Ingalls Memorial Hospital - Harvey

Maryland

  • University of Maryland - Greenebaum Comprehensive Cancer Center - Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore

Massachusetts

  • Dana-Farber Cancer Institute - Boston
  • Lowell General Hospital - Lowell

Michigan

  • Michigan Cancer Research Consortium (St. Joseph Mercy Hospital - Ann Arbor
  • West Michigan Cancer Center - Grand Rapids

Minnesota

  • Metro-Minnesota NCI Community Oncology Research Program - Minneapolis
  • Mayo Clinic, Rochester, MN - Rochester

California

  • UCSF - San Francisco

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 518 participants
Start Date 2017-06-21
Est. Completion 2026-07-31
Phase Phase 3

Sponsor

Alliance Foundation Trials

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02947685

The ClinicalTrials.gov registry entry for NCT02947685 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 227-participant average among 16 other Estrogen Receptor-positive Breast Cancer trials with a reported enrollment target (128% higher). The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Estrogen Receptor-positive Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Anastrozole is the first listed.

NCT02947685 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, Maryland.

Frequently Asked Questions

What is clinical trial NCT02947685 about?

NCT02947685 is a clinical study titled "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer". The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast ca...

What is the current status of trial NCT02947685?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2017-06-21. Estimated completion is 2026-07-31.

What conditions does trial NCT02947685 study?

This clinical trial studies the following conditions: Estrogen Receptor-positive Breast Cancer, Her 2 Positive Breast Cancer.

What interventions are being tested in trial NCT02947685?

The interventions under investigation include: Anastrozole (DRUG), letrozole (DRUG), palbociclib (DRUG), trastuzumab (DRUG), pertuzumab (DRUG).

Who is sponsoring clinical trial NCT02947685?

This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02947685 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Estrogen Receptor-positive Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Estrogen Receptor-positive Breast Cancer

All registered trials for this condition

Her 2 Positive Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.